Bicyclic compound, production and use thereof

Details Bicyclic compound, production and use thereof Bicyclic compound, production and use thereof

2008-05-13

2008-05-13

Coleman, Brenda L (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S397000, C514S459000, C540S476000

Reexamination Certificate

active

10484762

ABSTRACT:
The present invention provides a new cyclic compound having a CCR antagonist activity, especially a CCR5 antagonist activity, and the use thereof. The compound of the present invention is represented by the formula:wherein, R1is a 5- to 6-membered ring group which may be substituted; X1is a bond or the like; ring A is a 5- to 6-membered ring group which may be substituted; ring B is a 8- to 10-membered ring group which may be substituted; X2is a bivalent group of 1 to 4 atoms; Z1is a bivalent cyclic ring group or the like; Z2is a bond or the like; and R2is an amino group, a nitrogen-containing heterocyclic group which may be substituted or the like, or a salt thereof.

REFERENCES:
patent: WO-96/01267 (1996-01-01), None
patent: WO-99/32100 (1999-07-01), None
patent: WO-00/10965 (2000-03-01), None
Horuk, Richard, Chemokine Receptors, Cytokine and Growth Factor Reviews, vol. 12, No. 4, pp. 313-335, Dec. 2001.
R. Liu, et al., “Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection”, Cell, (1996), 86: 367-377.
M. Samson, et al., “Resistance to HIV-1 Infection in Caucasian Individuals Bearing Mutant Alleles of the CCR-5 Chemokine Receptor Gene”, Nature, (1996), 382: 722-725.
M. Baba, et al., “TAK-652 Inhibits CCR5-Mediated Human Immunodeficiency Virus Type 1 Infection In Vitro and Has Favorable Pharmacokinetics in Humans”, Antimicrobial Agents and Chemotherapy, (2005), pp. 4584-4591.
M. Fischereder, et al., “CC Chemokine Receptor 5 and Renal-Transplant Survival”, The Lancet (2001), 357: 1758-1761.
F. Sellebjerg, et al., “CCR5 Delta 32, Matrix Metalloproteinase-9 and Disease Activity in Multiple Sclerosis”, Journal of Neuroimmunology, (2000), pp. 98-106.
V. Pokorny, et al., “Evidence for Negative Association of the Chemokine Receptor CCR5 d32 Polymorphism with Rheumatoid Arthritis”, Ann. Rheum. Dis., (2005), 64: 487-490.
T.C. Dawson, et al., “Absence of CC Chemokine Receptor-2 Reduces Atherosclerosis in Apolipoprotein E-Deficient Mice”, Atherosclerosis, (1999), 143: 205-211.
K. Maeda, et al., “The Current Status of, and Challenges in, the Development of CCR5 Inhibitors as Therapeutics for HIV-1 Infection”, Current Opinion in Pharmacology, (2004), 4: 447-452.
K. Princen, et al., “HIV Chemokine Receptor Inhibitors as Novel anti-HIV Drugs”, Cytokine & Growth Factor Reviews, (2005), 16: 659-677.
W. Kazmierski, et al., “Recent Progress in Discovery of Small-Molecule CCR5 Chemokine Receptor Ligands as HIV-1 Inhibitors”, Bioorganic & Medicinal Chemistry, (2003), 11: 2663-2676.
M. Baba et al. “A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity,”Proc. Natl. Acad. Sci., vol. 96, pp. 5698-5703 (May 1999).
H. Fukushi et al., “Synthesis and Platelet-Activating Factor (PAF)-Antagonistic Activities of 1,4-Disubstituted Piperazine Derivatives,”Chem. Pharm. Bull., vol. 42, No. 3, pp. 541-550 (1994).

Affiliated with

Also associated with

Rating

Bicyclic compound, production and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Bicyclic compound, production and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bicyclic compound, production and use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3944348